PTNM staging system proposed to help communicate disease states including PD component, trauma component, non-PD component, and mode<\/p>\n<\/h3>\n
By Elana Gotkine HealthDay Reporter<\/b><\/p>\n
<\/b><\/p>\n
WEDNESDAY, Aug. 21, 2024 (HealthDay News) — In a review published in the June issue of The Journal of Urology<\/em>, a staging system is proposed for establishing Peyronie disease (PD) subtypes and non-PD penile curvature classifications.<\/p>\n In an effort to improve the classification of PD and non-PD penile curvature, Landon Trost, M.D., from the Male Fertility and Peyronie’s Clinic in Orem, Utah, and colleagues conducted a retrospective review of 1,098 men who presented with penile deformity. A second cohort of 719 men was used to examine the relapsing\/remitting subtype.<\/p>\n Four distinct subtypes of PD were identified: classical and nonclassical; calcifying; progressive; and relapsing\/remitting, with reactivation following at least six months of stability. Non-PD categorizations included congenital, maturational, and trauma induced. The authors found that penile pain was not a reliable predictor of disease progression or stability. The definition of stable phase disease varied by subtype: classical (at least three months) or progressive, calcifying, or trauma induced (at least 12 months plus at least three months stable or<\/em> at least six months stable). At at least three months following disease onset, PD subtypes could be assigned. To help communicate disease states, a PTNM staging system was proposed: P = PD component (calcifying, classical, progressive, relapsing\/remising, undifferentiated); T = trauma component (present or absent): N = non-PD component (congenital, maturational, undifferentiated); and M = mode (stable or active).<\/p>\n “We believe our proposed PTNM system will be clinically helpful in the evaluation and management of men with penile curvature,” Trost said in a statement. “This information has the potential to improve prognostic information, enhance patient counseling, and facilitate treatment decision-making for patients with PD, as well as guiding further research.”<\/p>\n Abstract\/Full Text<\/a><\/p>\n Editorial 1 (subscription or payment may be required)<\/a><\/p>\n Editorial 2 (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n